The Merck & Co., Inc. (MRK) Shares Sold by Douglass Winthrop Advisors LLC, Report finds

The Merck & Co., Inc. (MRK) Shares Sold by Douglass Winthrop Advisors LLC, Report finds

A number of other institutional investors also recently modified their holdings of the company. NewSquare Capital LLC raised its position in shares of Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock valued at $121,000 after buying an additional 261 shares during the period. Wagner Bowman Management Corp raised its position in shares of Merck & Co. by 1.0% in the second quarter. Wagner Bowman Management Corp now owns 23,668 shares of the company’s stock valued at $1,363,000 after buying an additional 228 shares during the period. Investment House LLC raised its position in shares of Merck & Co. by 3.4% in the second quarter. Investment House LLC now owns 61,812 shares of the company’s stock valued at $3,561,000 after buying an additional 2,029 shares during the period. Pitcairn Co. raised its position in shares of Merck & Co. by 1.8% in the second quarter. Pitcairn Co. now owns 29,036 shares of the company’s stock valued at $1,673,000 after buying an additional 520 shares during the period. Finally, Stoneridge Investment Partners LLC raised its position in shares of Merck & Co. by 79.1% in the second quarter. Stoneridge Investment Partners LLC now owns 16,525 shares of the company’s stock valued at $952,000 after buying an additional 7,300 shares during the period. 73.80% of the stock is owned by hedge funds and other institutional investors.

Douglass Winthrop Advisors LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK) by 1.9% during the third quarter, Holdings Channel reports. The firm owned 345,544 shares of the company’s stock after selling 6,803 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Merck & Co. were worth $21,565,000 as of its most recent SEC filing.

Shares of Merck & Co., Inc. (NYSE:MRK) traded up 0.11% during mid-day trading on Thursday, reaching $64.39. 7,052,880 shares of the company traded hands. The stock’s 50 day moving average is $61.47 and its 200 day moving average is $61.68. The stock has a market capitalization of $177.53 billion, a PE ratio of 31.56 and a beta of 0.79. Merck & Co., Inc. has a 52-week low of $48.28 and a 52-week high of $65.46.

Merck & Co. (NYSE:MRK) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.89 EPS for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.00. Merck & Co. had a net margin of 14.30% and a return on equity of 24.08%. The company had revenue of $10.10 billion for the quarter, compared to analyst estimates of $10.22 billion. During the same quarter last year, the firm posted $0.93 earnings per share. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, analysts anticipate that Merck & Co., Inc. will post $3.81 earnings per share for the current year.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $73.00 price objective for the company in a research report on Friday, November 11th. Vetr raised shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $66.07 price objective for the company in a research report on Tuesday, November 15th. Jefferies Group LLC lowered shares of Merck & Co. from a “hold” rating to an “underperform” rating and set a $48.00 price objective for the company. in a research report on Monday, December 19th. Bryan, Garnier & Co assumed coverage on shares of Merck & Co. in a research report on Friday, January 13th. They issued a “buy” rating for the company. Finally, Leerink Swann reissued a “market perform” rating and issued a $65.00 price objective on shares of Merck & Co. in a research report on Wednesday, October 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $66.91.

In related news, EVP Michael J. Holston sold 91,959 shares of the business’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $63.96, for a total transaction of $5,881,697.64. Following the transaction, the executive vice president now owns 105,559 shares of the company’s stock, valued at $6,751,553.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patricia F. Russo sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 8th. The stock was sold at an average price of $64.42, for a total transaction of $322,100.00. Following the transaction, the director now directly owns 18,148 shares in the company, valued at approximately $1,169,094.16. The disclosure for this sale can be found here. In the last three months, insiders sold 106,959 shares of company stock worth $6,843,448. Insiders own 0.05% of the company’s stock.

Merck & Co. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Related posts

Leave a Comment